Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
Neuromolecular Med ; 20(3): 281-300, 2018 09.
Article in English | MEDLINE | ID: mdl-30022304

ABSTRACT

The astrocyte-neuron lactate shunt (ANLS) hypothesis is the most widely accepted model of brain glucose metabolism. However, over the past decades, research has shown that neuronal and astrocyte plasma membrane receptors, in particular, GLUT2, Kir6.2 subunit of the potassium ATP-channel, SGLT-3 acting as glucosensors, play a pivotal role in brain glucose metabolism. Although both ANLS hypothesis and glucosensor model substantially improved our understanding of brain glucose metabolism, the latter appears to be gaining more attention in the scientific community as the former could not account for new research data indicating that hypothalamic and brainstem neurons may not require astrocyte-derived lactate for energy. More recently, emerging evidences suggest a crucial role of sweet taste receptors in brain glucose metabolism. Furthermore, a couple of intracellular molecules acting as glucosensors have been identified in central astrocytes and neurons. This review integrates new data on the mechanisms of brain glucose sensing and metabolism. The role of the glucosensors including the sweet taste T1R2 + T1R3-mediated brain glucose-sensing and metabolism in brain glucose metabolic disorders is discussed. Possible role of glucose sensors (GLUT2, K-ATPKir6.2, SGLT3, T1R2 + T1R3) in brain diseases involving metabolic dysfunctions and the therapeutic significance in targeting central glucosensors for the treatment of these brain diseases are also discussed.


Subject(s)
Astrocytes/metabolism , Brain Diseases/metabolism , Brain/metabolism , Glucose/metabolism , Neurons/metabolism , Receptors, G-Protein-Coupled/physiology , Taste , Brain Diseases/drug therapy , Energy Metabolism , Glucose Transporter Type 2/metabolism , Glucose Transporter Type 2/therapeutic use , Humans , Potassium Channels, Inwardly Rectifying/metabolism , Potassium Channels, Inwardly Rectifying/therapeutic use , Sodium-Glucose Transport Proteins/metabolism , Sodium-Glucose Transport Proteins/therapeutic use
2.
Acta Cir Bras ; 33(2): 175-184, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29513816

ABSTRACT

PURPOSE: To investigate the effects of aquaporin 4 (AQP4) and inward rectifier potassium channel 4.1 (Kir4.1) on medullospinal edema after treatment with methylprednisolone (MP) to suppress acute spinal cord injury (ASCI) in rats. METHODS: Sprague Dawley rats were randomly divided into control, sham, ASCI, and MP-treated ASCI groups. After the induction of ASCI, we injected 30 mg/kg MP via the tail vein at various time points. The Tarlov scoring method was applied to evaluate neurological symptoms, and the wet-dry weights method was applied to measure the water content of the spinal cord. RESULTS: The motor function score of the ASCI group was significantly lower than that of the sham group, and the spinal water content was significantly increased. In addition, the levels of AQP4 and Kir4.1 were significantly increased, as was their degree of coexpression. Compared with that in the ASCI group, the motor function score and the water content were significantly increased in the MP group; in addition, the expression and coexpression of AQP4 and Kir4.1 were significantly reduced. CONCLUSION: Methylprednisolone inhibited medullospinal edema in rats with acute spinal cord injury, possibly by reducing the coexpression of aquaporin 4 and Kir4.1 in medullospinal tissues.


Subject(s)
Aquaporin 4/metabolism , Edema/drug therapy , Glucocorticoids/pharmacology , Methylprednisolone/pharmacology , Potassium Channels, Inwardly Rectifying/metabolism , Spinal Cord Diseases/drug therapy , Spinal Cord Injuries/drug therapy , Acute Disease , Animals , Aquaporin 4/therapeutic use , Disease Models, Animal , Edema/metabolism , Fluorescent Antibody Technique , Glucocorticoids/therapeutic use , Male , Methylprednisolone/therapeutic use , Potassium Channels, Inwardly Rectifying/therapeutic use , Random Allocation , Rats , Rats, Sprague-Dawley , Spinal Cord/cytology , Spinal Cord/drug effects , Spinal Cord Diseases/metabolism , Spinal Cord Injuries/chemically induced
3.
Acta cir. bras ; 33(2): 175-184, Feb. 2018. graf
Article in English | LILACS | ID: biblio-886262

ABSTRACT

Abstract Purpose: To investigate the effects of aquaporin 4 (AQP4) and inward rectifier potassium channel 4.1 (Kir4.1) on medullospinal edema after treatment with methylprednisolone (MP) to suppress acute spinal cord injury (ASCI) in rats. Methods: Sprague Dawley rats were randomly divided into control, sham, ASCI, and MP-treated ASCI groups. After the induction of ASCI, we injected 30 mg/kg MP via the tail vein at various time points. The Tarlov scoring method was applied to evaluate neurological symptoms, and the wet-dry weights method was applied to measure the water content of the spinal cord. Results: The motor function score of the ASCI group was significantly lower than that of the sham group, and the spinal water content was significantly increased. In addition, the levels of AQP4 and Kir4.1 were significantly increased, as was their degree of coexpression. Compared with that in the ASCI group, the motor function score and the water content were significantly increased in the MP group; in addition, the expression and coexpression of AQP4 and Kir4.1 were significantly reduced. Conclusion: Methylprednisolone inhibited medullospinal edema in rats with acute spinal cord injury, possibly by reducing the coexpression of aquaporin 4 and Kir4.1 in medullospinal tissues.


Subject(s)
Animals , Male , Rats , Spinal Cord Diseases/drug therapy , Spinal Cord Injuries/drug therapy , Methylprednisolone/pharmacology , Potassium Channels, Inwardly Rectifying/metabolism , Edema/drug therapy , Aquaporin 4/metabolism , Glucocorticoids/pharmacology , Spinal Cord/cytology , Spinal Cord/drug effects , Spinal Cord Diseases/metabolism , Spinal Cord Injuries/chemically induced , Methylprednisolone/therapeutic use , Random Allocation , Acute Disease , Fluorescent Antibody Technique , Rats, Sprague-Dawley , Potassium Channels, Inwardly Rectifying/therapeutic use , Disease Models, Animal , Edema/metabolism , Aquaporin 4/therapeutic use , Glucocorticoids/therapeutic use
4.
Arq Bras Endocrinol Metabol ; 52(2): 181-7, 2008 Mar.
Article in Portuguese | MEDLINE | ID: mdl-18438528

ABSTRACT

Neonatal diabetes is a rare condition characterized by hyperglycemia, requiring insulin treatment, diagnosed within the first months of life. The disorder may be either transient, resolving in infancy or early childhood with possible relapse later, or permanent in which case lifelong treatment is necessary. Both conditions are genetically heterogeneous; however, the majority of the cases of transient neonatal diabetes are due to abnormalities of an imprinted region of chromosome 6q24. For permanent neonatal diabetes, the most common causes are heterozygous activating mutations of KCNJ11, the gene encoding the Kir6.2 sub-unit of the ATP-sensitive potassium channel. In this article we discuss the clinical features of neonatal diabetes, the underlying genetic defects and the therapeutic implications.


Subject(s)
Diabetes Mellitus/genetics , Mutation , Diabetes Mellitus/drug therapy , Homeodomain Proteins/genetics , Humans , Hypoglycemic Agents/therapeutic use , Infant, Newborn , Insulin/genetics , Insulin/therapeutic use , KATP Channels/genetics , Potassium Channels, Inwardly Rectifying/genetics , Potassium Channels, Inwardly Rectifying/therapeutic use , Tolbutamide/therapeutic use , Trans-Activators/genetics
5.
Arq. bras. endocrinol. metab ; 52(2): 181-187, mar. 2008.
Article in Portuguese | LILACS | ID: lil-480990

ABSTRACT

O diabetes neonatal (DN) é uma condição rara caracterizada por hiperglicemia, que necessita de tratamento com insulina, diagnosticado nos primeiros meses de vida. Clinicamente pode ser classificado em DN transitório quando ocorre remissão da doença em poucos meses, podendo haver recorrência posterior; ou permanente quando, como o nome indica, não ocorre remissão. Ambas as condições são geneticamente heterogêneas; entretanto a maioria dos casos de DN transitório é decorrente de anormalidades da região de imprinted no cromossomo 6q24. Mutações ativadoras em heterozigose no gene KCNJ11, que codifica a subunidade Kir6.2 do canal de potássio ATP-sensível, são a causa mais comum de DN permanente. No presente artigo, discutimos as características clínicas do DN, os mecanismos moleculares envolvidos e suas implicações terapêuticas.


Neonatal diabetes is a rare condition characterized by hyperglycemia, requiring insulin treatment, diagnosed within the first months of life. The disorder may be either transient, resolving in infancy or early childhood with possible relapse later, or permanent in which case lifelong treatment is necessary. Both conditions are genetically heterogeneous; however, the majority of the cases of transient neonatal diabetes are due to abnormalities of an imprinted region of chromosome 6q24. For permanent neonatal diabetes, the most common causes are heterozygous activating mutations of KCNJ11, the gene encoding the Kir6.2 sub-unit of the ATP-sensitive potassium channel. In this article we discuss the clinical features of neonatal diabetes, the underlying genetic defects and the therapeutic implications.


Subject(s)
Humans , Infant, Newborn , Diabetes Mellitus/genetics , Mutation , Diabetes Mellitus/drug therapy , Homeodomain Proteins/genetics , Hypoglycemic Agents/therapeutic use , Insulin/genetics , Insulin/therapeutic use , KATP Channels/genetics , Potassium Channels, Inwardly Rectifying/genetics , Potassium Channels, Inwardly Rectifying/therapeutic use , Tolbutamide/therapeutic use , Trans-Activators/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...